Faculty profile

Morag Park

ResearcherOncologyMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Morag Park

Researcher

Oncology

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
54 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 6 research grants (6 CIHR), most recently in 2024.
Supervisor on 5 trainee awards (5 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

166

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Triple Negative Breast Cancer Patient Derived Xenografts Intracellular Trafficking Oncogenic Activation Receptor Tyrosine Kinase Bioinformatics Chemotherapy-Induced Senescence Drug Tolerant Persistor Cells

Latest papers

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.
Cell reports. Medicine · 2026
Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.
Cell reports. Medicine · 2026
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.
Cancer treatment reviews · 2026

All 166 publications

Latest funding

Targeting EZH2 in breast cancer: Role of epigenetic modification in modulating breast cancer cell plasticity.
CIHR · 2025 · Co-investigator
$100,000
Targeting drug tolerant persister cells in poor outcome breast cancer
CIHR · 2024 · Nominated PI
$1,136,025
Targeting atypical B7 family checkpoints in poor-outcome triple-negative breast cancers
CIHR · 2023 · Co-investigator
$1,051,875

All 22 grants and awards

From the 150 most recent of 166 publications.

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.

Saatci O, Ulukan B, Cetin M, Kuasne H, Martinez C, Percin E, Oleinik N, Savoca MT, Nehme A, Hernández-Corchado A, Zavacky E, Sreenivas K, Rezaeian AH, Bethard JR, Anoma JS, Sahin OS, Aguilar-Mahecha A, Buchanan M, Aras M, DeBlois G, Basik M, Hill EG, Ball LE, Rao CN, McInnes C, Riazalhosseini Y, Najafabadi HS, Lemasters JJ, Ogretmen B, Park M, Sahin O

Cell reports. Medicine2026

DOI: 10.1016/j.xcrm.2026.103015 PMID: 42673947

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.

Taifour T, Gu Y, Massé A, Meng X, Echavez CD, Zuo D, Sanguin-Gendreau V, Blouin A, Graham-Paquin AL, Addie M, Solymoss E, Xiao B, Proud H, Attalla SS, Nam AJ, Papavasiliou V, Kuasne H, Siegel PM, Keyomarsi K, McCaffrey L, Park M, Muller WJ

Cell reports. Medicine2026

DOI: 10.1016/j.xcrm.2026.103050 PMID: 42727582

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Romero JM, Magrill J, Kalashnikov N, Luo YZ, Chen OJ, Busque S, Ma R, Atallah A, Lazaratos AM, Mendelson D, Wilson L, Deshmukh S, Taifour T, Sorin M, Arthur I, Kuasne H, Levett JY, Wang Y, Seufferlein T, Kleger A, Gout J, Michels AK, Brugarolas J, Poshusta ZS, Hogenson TL, Fernandez-Zapico ME, Hamada A, Yagishita S, Kryeziu K, Lothe RA, Nichols A, Barrett JW, Papaccio F, Castillo J, Inoue M, Massfelder T, Lang H, Lindner V, Nilsson J, Dantes Z, Seppanen H, Wells GA, Kim SH, Ittmann MM, Villanueva H, Lerner SP, Sikora AG, Theillet C, Huang DQ, Khuong-Quang DA, Yeung JC, Park M, Siegel PM, Watson IR, Zogopoulos G, Rose AAN, Dankner M

Cancer treatment reviews2026

DOI: 10.1016/j.ctrv.2026.103190 PMID: 42497819

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.

Nobrega M, Kuasne H, Souza MF, Reis MBD, Oliveira LCB, Fuganti PE, Park M, Cólus IMS

Non-coding RNA2026

DOI: 10.3390/ncrna12050033 PMID: 42776739

A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer.

Bahl S, Dogan-Artun N, Nguyen J, Mahmoud H, Ba-Alawi W, Madani Tonekaboni SA, Kang KK, McGuire M, Tobin C, Silvester J, Savage P, Cressot L, Nand A, Feng G, Guilhamon P, Mer AS, Arlidge C, Elliott MJ, Park M, Cescon DW, Haibe-Kains B, Lupien M

Nature communications2026

DOI: 10.1038/s41467-026-76385-8 PMID: 42749733

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.

Ulukan B, Saatci O, Madrigal A, Kim M, Tian W, Soytas M, Mehrjoo Z, Sahin OS, Sreenivas K, Rao CN, Nishimura T, Pillon V, Anoma JS, Hill E, Rak J, McInnes C, Park M, Brimo F, Tanguay S, Russell RC, Najafabadi H, Riazalhosseini Y, Sahin O

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.07.24.739825 PMID: 42582009

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

Aceto G, Liu K, Arabzadeh A, Tsai S, Xue Y, Monast A, Pilon V, Han M, Morin G, Pavlakis K, Fu L, Park M, Foulkes WD, Wang Y, Huang S

Nature communications2026

DOI: 10.1038/s41467-026-74204-8 PMID: 42297809

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

Maritan SM, Karimi E, Dankner M, Hernandez-Corchado A, Yu MW, Annis MG, Aghazadeh Habashi Y, Rezanejad M, Liu B, Koudieh N, Pichette E, Fallah P, Fiset B, Wei Y, Nehme A, Lee CG, Elias JA, Park M, Riazalhosseini Y, Najafabadi H, Petrecca K, Guiot MC, Quail DF, Walsh LA, Siegel PM

JCI insight2026

DOI: 10.1172/jci.insight.199498 PMID: 42171608

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

Guay J, Kuasne H, Chabot C, Bozek K, Majedi Y, Buchanan M, Aguilar-Mahecha A, Bareke E, Ulmer B, Kong T, Yang K, Liao M, Elebute O, Guo R, Monast A, Morin G, Huang S, Park M, Basik M

Cancer research communications2026

DOI: 10.1158/2767-9764.crc-25-0044 PMID: 41973002

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Jiang J, Zhu X, Fu Z, Liao M, Arabzadeh A, Robert F, Monast A, Pilon V, Pavlakis K, Park M, Foulkes WD, Huang S

NPJ precision oncology2026

DOI: 10.1038/s41698-026-01350-z PMID: 41807550

Something wrong or missing on this profile? Suggest a correction

Morag Park

Research

Latest papers

Latest funding

Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.

Neutrophil elastase-mediated myoepithelial loss is a therapeutic vulnerability in ductal carcinoma in situ progression.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Circulating Cell-Free miR-25-3p Is Upregulated in Brazilian Patients with Prostate Cancer and Contributes to Tumor Aggressiveness.

A chromatin-informed transcriptional regulatory framework to stratify patients and guide therapy selection in triple-negative breast cancer.

Lysyl oxidase drives ccRCC progression by coordinating HIF-2&#x3b1; transcription program with tumor microenvironment.

SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.

Distinct immune landscapes characterize highly versus minimally invasive brain metastases.

ATR and PKMYT1 Inhibition Resensitizes a Subset of TNBC Patient-Derived Models to Carboplatin, Inducing Mitotic Catastrophe.

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Frequent collaborators

Morag Park

Sidong Huang

ATILLA Omeroglu

Mark Basik

Sarkis Meterissian

Kevin Petrecca

Benjamin Haibe-Kains

Guillaume Bourque

Anne-Claude Gingras

Janusz Rak

Kevin Petrecca

Julie St-Pierre

Christopher Moraes

Elena Kuzmin

Yasser Riazalhosseini

Yemin Wang

Jerry Pelletier

Xiang-Jiao Yang

Julie St-Pierre

Luke McCaffrey

Alain Nepveu

Kalle Gehring

Nahum Sonenberg

Mathieu Lupien

Lorenzo Ferri

Michael Witcher

William Lockwood

Lynne-Marie Postovit

Ivan Topisirovic

Shawn McGuirk

Jonathan Spicer

Catalin Mihalcioiu

Igor Stagljar

Igor Jurisica

David Huntsman

Nicole Beauchemin

Mark Lathrop

William Muller

Jean-Yves Masson

Rongtuan Lin

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.